These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 18362931)

  • 61. A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).
    Lima J; Jenkins C; Guerrero A; Triozzi PL; Shaw DR; Strong TV
    Vaccine; 2005 Jan; 23(10):1273-83. PubMed ID: 15652670
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
    Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
    Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis c.
    Carreño V; Martín J; Pardo M; Brotons A; Anchía P; Navas S; Fernández M; Arocena C; Quiroga JA
    Cytokine; 2000 Feb; 12(2):165-70. PubMed ID: 10671303
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors.
    Urdinguio RG; Fernandez AF; Moncada-Pazos A; Huidobro C; Rodriguez RM; Ferrero C; Martinez-Camblor P; Obaya AJ; Bernal T; Parra-Blanco A; Rodrigo L; Santacana M; Matias-Guiu X; Soldevilla B; Dominguez G; Bonilla F; Cal S; Lopez-Otin C; Fraga MF
    Cancer Res; 2013 Jan; 73(1):395-405. PubMed ID: 23108143
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Tumour-derived exosomes and their roles in cancer].
    Wang K; Tang J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Dec; 35(12):1288-92. PubMed ID: 21200099
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
    Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
    Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
    Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
    Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.
    Morse MA; Deng Y; Coleman D; Hull S; Kitrell-Fisher E; Nair S; Schlom J; Ryback ME; Lyerly HK
    Clin Cancer Res; 1999 Jun; 5(6):1331-8. PubMed ID: 10389916
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
    Fong L; Kwek SS; O'Brien S; Kavanagh B; McNeel DG; Weinberg V; Lin AM; Rosenberg J; Ryan CJ; Rini BI; Small EJ
    Cancer Res; 2009 Jan; 69(2):609-15. PubMed ID: 19147575
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
    Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
    Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
    [TBL] [Abstract][Full Text] [Related]  

  • 72. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.
    Simmons SJ; Tjoa BA; Rogers M; Elgamal A; Kenny GM; Ragde H; Troychak MJ; Boynton AL; Murphy GP
    Prostate; 1999 Jun; 39(4):291-7. PubMed ID: 10344219
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Autoantibody against granulocyte-macrophage colony-stimulating factor and other serum markers in pulmonary alveolar proteinosis].
    Xu KF; Chen Y; Guo ZJ; Zhu YJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Dec; 27(12):824-8. PubMed ID: 15730782
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Granulocyte macrophage-colony stimulating factor (GM-CSF) in diagnosis and monitoring of non-small cell lung cancer].
    Mroczko B; Szmitkowski M; Furman M; Czygier M
    Pol Arch Med Wewn; 1998 Mar; 99(3):195-202. PubMed ID: 9760805
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
    Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
    Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
    Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
    Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
    Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Construction of recombinant plasmid pIRES-GM-CSF-IL-21 and its therapeutic effect on orthotopically transplanted liver cancer in mice].
    Cheng MR; Li Q; Hong XW; Ye T; He B; Cheng ZJ; Xu HZ; Zha BB
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):661-5. PubMed ID: 22340045
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF.
    Wadhwa M; Mellstedt H; Small E; Thorpe R
    Dev Biol (Basel); 2003; 112():61-7. PubMed ID: 12762505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.